NCT01106872View on ClinicalTrials.gov

Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas

PHASE1CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

July 31, 2017

Study Completion Date

August 22, 2017

Conditions
SarcomaSoft Tissue SarcomaLocally Advanced SarcomaUnresectable SarcomaMetastatic Sarcoma
Interventions
DRUG

Bevacizumab, Gemcitabine, Docetaxel and Valproic Acid

Trial Locations (1)

52242

University of Iowa Hospitals and Clinics, Iowa City

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Mohammed M Milhem

OTHER

NCT01106872 - Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas | Biotech Hunter | Biotech Hunter